World Book and News -- ORLANDO -- Targeted nanoparticle technology demonstrated its potential as a vehicle for intraperitoneal chemoradiation for ovarian cancer, according to results from a preclinical model presented here. Experiments in mice, using chemotherapy alone, radiotherapy alone, and a combination of both, consistently resulted in lower tumor-cell survival with targeted nanoparticle-encapsulated treatment versus untargeted therapy, reported Michael Werner, PhD, of the University of North Carolina in Chapel Hill, and colleagues.
